生物
肾透明细胞癌
DNA甲基化
肾细胞癌
甲基化
癌症研究
基因
基因表达谱
PI3K/AKT/mTOR通路
基因表达
遗传学
分子生物学
信号转导
病理
医学
作者
Yusuke Sato,Tetsuichi Yoshizato,Yuichi Shiraishi,Shigekatsu Maekawa,Yusuke Okuno,Takumi Kamura,Teppei Shimamura,Aiko Sato‐Otsubo,Genta Nagae,Hiromichi Suzuki,Yasunobu Nagata,Kenichi Yoshida,Ayana Kon,Yutaka Suzuki,Kenichi Chiba,Hiroko Tanaka,Atsushi Niida,Akihiro Fujimoto,Tatsuhiko Tsunoda,Teppei Morikawa
出处
期刊:Nature Genetics
[Nature Portfolio]
日期:2013-06-24
卷期号:45 (8): 860-867
被引量:1103
摘要
Clear-cell renal cell carcinoma (ccRCC) is the most prevalent kidney cancer and its molecular pathogenesis is incompletely understood. Here we report an integrated molecular study of ccRCC in which ≥100 ccRCC cases were fully analyzed by whole-genome and/or whole-exome and RNA sequencing as well as by array-based gene expression, copy number and/or methylation analyses. We identified a full spectrum of genetic lesions and analyzed gene expression and DNA methylation signatures and determined their impact on tumor behavior. Defective VHL-mediated proteolysis was a common feature of ccRCC, which was caused not only by VHL inactivation but also by new hotspot TCEB1 mutations, which abolished Elongin C-VHL binding, leading to HIF accumulation. Other newly identified pathways and components recurrently mutated in ccRCC included PI3K-AKT-mTOR signaling, the KEAP1-NRF2-CUL3 apparatus, DNA methylation, p53-related pathways and mRNA processing. This integrated molecular analysis unmasked new correlations between DNA methylation, gene mutation and/or gene expression and copy number profiles, enabling the stratification of clinical risks for patients with ccRCC.
科研通智能强力驱动
Strongly Powered by AbleSci AI